The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate

Clin Exp Rheumatol. Sep-Oct 2003;21(5 Suppl 31):S195-7.

Abstract

The Early Rheumatoid Arthritis (ERA) trial compared monotherapy with etanercept or methotrexate in patients with early erosive rheumatoid arthritis. Over the initial period of 12, and subsequently 24, months both treatments were associated with a profound reduction in radiographic progression of joint damage, as well as a reduction in signs and symptoms of disease. Etanercept showed slight superiority to methotrexate in reducing subsequent radiographic erosions and in the rapidity of the clinical response. Both therapies proved to be safe and well tolerated and, importantly, the relative safety and tolerance of a rapidly escalated dosing regimen for methotrexate was demonstrated. In summary, early aggressive treatment of RA is associated with clinical and radiographic benefit that can be demonstrated after a relatively short period of treatment.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Arthritis, Rheumatoid / diagnosis*
  • Arthritis, Rheumatoid / drug therapy*
  • Controlled Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Etanercept
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G / administration & dosage*
  • Immunoglobulin G / adverse effects
  • Male
  • Maximum Tolerated Dose*
  • Methotrexate / administration & dosage*
  • Methotrexate / adverse effects
  • Receptors, Tumor Necrosis Factor / administration & dosage*
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept
  • Methotrexate